Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$11M
- −293.0% YoY · −19.8% QoQ
- EPS (diluted)
- −$1.03
- +52.1% YoY · −19.8% QoQ
Source: XBRL data from the PALVELLA THERAPEUTICS, INC. (PVLA) Q3 2025 10-Q on SEC EDGAR. USD.
PALVELLA THERAPEUTICS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or changed risk factors from 2024 Form 10-K disclosed this quarter
- Regulatory/legal risk focus unchanged; no new defaults or safety disclosures reported
- Operational risk: insider Rule 10b5-1 trading plan adopted by COO for sale of up to 51,635 shares
- Financial risk: no material changes, no unregistered sales or issuer repurchases this quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PALVELLA THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.